© Owkin Inc 2019 Owkin SocratesOWKIN: Predictive Medicine & Machine Learning

May 2019. Owkin provide expertise in artificial intelligence and machine learning to our partners, augmenting their R&D skills so that they can leverage our services to unlock the power of AI on existing and future data. Our services include data science and technology assessments, specific target and molecule discovery projects and usage of real-world data for clinical trial optimization. We collaborate with our partners on AI-based publications.

OWKIN Socrates is our flagship technology platform, engineered to be comprehensive and easily usable by non machine learning experts to perform AI projects and deliver production level predictive models. Empowered by state-of-the-art machine learning and deep learning algorithms, users can easily create predictive models and optimize drug development at every stage, from survival prognosis to target discovery, patient recruitment for clinical trials to post-market analysis. Combining algorithmic excellence with unique access to real-world data, OWKIN Socrates integrates powerful pre-trained models using proprietary privacy-preserving transfer and federated learning technologies.

Source: Owkin France SAS 

Back to section

Other Articles Recommended

 B2Bioworld offers you background information

Regulatory Challenges of Big Data Operations – Algorithms, Healthcare, or Autonomous Driving
Herbert Zech, Professor of Life Sciences and Intellectual Property Laws at Universität Basel on key juridical concepts of the current debate about big data and artificial intelligence applications beyond privacy laws

AI-enabled Digital Pathology: Correlate anything with everything?
Ralf Huss, Chief Medical Officer Definiens AG. Interview and Comment: Automated and Whole Slide Imaging for Pathology 2018

Steering Health Data For or By? The User as Stakeholder, Expert, Citizen, Consumer, and Patient
Thomas D. Szucs, Chairman of Helsana Group, one of the largest Swiss health insurance companies, on making “big data” work and crossing traditional boundaries of managing information assets

Clarifying the concept of personalised medicine
Jonathan Knowles, past Member of the Roche Executive Committee and Head of Group Research

Transition Cancer Research Translation
Christof von Kalle, Head of Germany’s National Center for Tumor Diseases on transitions in translational cancer research

Opening up Emerging Markets for Rapid Diagnostics and Point-of-Care Assays
David Dolinger shares experience and insight. Do’s and Don’ts in developing viable tests for medical, agricultural, or food diagnostics, and bringing these to low resource countries

Metrics for Disease, Health, and Wellness
Personalized medicine? A systems look at human genetic diagnostics and the road ahead for next-generation sequencing by Leroy Hood, Institute for Systems Biology at Seattle

Crowd Sourcing Actionable Health Diagnoses
Dekel Gelbman, CEO of the FDNA Group on applying mobile face resp. pattern recognition for discovering individuals with genetic pathologies and rare diseases

Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only. Their inclusion on B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.